^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Microtubule inhibitor

    Related drugs:
    1d
    TSL-B2276-1-01: A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=19, Completed, Tasly Pharmaceutical Group Co., Ltd | Recruiting --> Completed | N=132 --> 19 | Trial completion date: Dec 2027 --> Dec 2025 | Trial primary completion date: Dec 2026 --> Jun 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    luveltamab tazevibulin (STRO-002)
    4d
    Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P2, N=126, Completed, Beijing Biostar Pharmaceuticals Co., Ltd. | Recruiting --> Completed | Trial completion date: Dec 2024 --> May 2025 | Trial primary completion date: Mar 2024 --> May 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    utidelone IV (UTD1)
    4d
    Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients (clinicaltrials.gov)
    P2, N=58, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    Adcetris (brentuximab vedotin)
    4d
    Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance (clinicaltrials.gov)
    P2, N=29, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    Tyvyt (sintilimab) • capecitabine • Aidixi (disitamab vedotin)
    5d
    [177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study. (PubMed, Lancet Oncol)
    Multicycle [177Lu]Lu-PSMA-617 and pembrolizumab showed encouraging activity with manageable toxicity that was consistent with [177Lu]Lu-PSMA-617 or pembrolizumab, and the combination might provide durable clinical benefit in a subset of patients.
    P1/2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    |
    Keytruda (pembrolizumab) • docetaxel • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    5d
    DTP-HER2: A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer (clinicaltrials.gov)
    P2, N=76, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Tevimbra (tislelizumab-jsgr) • Aidixi (disitamab vedotin) • Kolupin (tunlametinib)
    5d
    Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive Metastatic Tumor Patients With Oligometastases (clinicaltrials.gov)
    P3, N=200, Recruiting, Ming-Yuan Chen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor)
    |
    Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    6d
    USP5 regulates purine metabolism and represents a therapeutic target in esophageal cancer. (PubMed, Cell Death Dis)
    Combination treatment with mebendazole and oxaliplatin significantly enhanced chemosensitivity in ESCC cells. Collectively, these findings establish the USP5-IMPDH2-guanine axis as a critical driver of ESCC progression and highlight its potential as a promising therapeutic target for ESCC.
    Journal
    |
    USP5 (Ubiquitin Specific Peptidase 5)
    |
    oxaliplatin • mebendazole
    6d
    Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (clinicaltrials.gov)
    P2, N=59, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • docetaxel • Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    6d
    cHL-PG01: A phase-2 academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab or pembrolizumab in relapsed or refractory classical Hodgkin lymphoma (cHL) (2024-520123-83-01)
    P1/2, N=48, Active, not recruiting, Universita' Degli Studi Di Perugia | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    Keytruda (pembrolizumab) • Jakafi (ruxolitinib) • Adcetris (brentuximab vedotin)
    6d
    CABA-DOC: Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer (clinicaltrials.gov)
    P3, N=195, Completed, Gustave Roussy, Cancer Campus, Grand Paris | Unknown status --> Completed
    Trial completion
    |
    docetaxel • cabazitaxel
    7d
    Tumor Cell Membrane-Camouflaged Nanoparticles Co-delivering Docetaxel and Metformin for Enhanced Synergistic Therapy of HER2-positive Breast Cancer. (PubMed, Pharm Dev Technol)
    In vivo, the system prolonged the circulation half-life to nearly 6 hours, effectively suppressed tumor growth, and demonstrated excellent biocompatibility with no significant toxicity or body weight loss. In conclusion, mem(DTX&Met@MSNs) integrates homologous targeting with dual-drug synergism, offering a safe and effective strategy for the treatment of HER2-positive breast cancer.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    docetaxel • metformin